The article, “The State of the Absorb Bioresorbable Scaffold: Consensus From an Expert Panel,” discusses the Absorb biodegradable scaffold, which came on the market as an alternative to permanent metallic stents. Abbott Vascular, maker of the Absorb scaffold, announced in September that it was ending distribution of the product due to low sales, although research on their efficacy continues.
The paper noted that concerns about heightened thrombosis risks were valid and needed further study, while noting similar concerns arose during the first generation of metallic stents. It concluded that the need for biodegradable scaffolds remains and that refined procedures and more rigorous patient selection could likely address or mitigate some concerns about the scaffolds.
Drs. Chehab and Maksoud, who practice with Cardiovascular Consultants of Kansas, were among 45 physicians serving on the expert panel.